Background. Chinese diabetic patients are at greater risk of developing chronic kidney disease (CKD) than Caucasian counterparts. In this hypothesis-generating study, we examined the independent and joint effects of multiple genetic variants on CKD in a prospective Chinese cohort of Type 2 diabetic patients. Methods. Seventy-seven single-nucleotide polymorphisms (SNPs) of 54 candidate genes for cardiorenal diseases and inflammation were genotyped in 1163 patients with no past history of CKD at baseline. CKD was defined as the first estimated glomerular filtration rate <60mL/min/1.73m 2 or the first hospitalization with a diagnosis of renal disease. Results. In Cox-regression analysis, 15 SNPs of 13 genes were associated with incident CKD. After correction for multiple comparisons, 6 SNPs including PON1 55Met, PON2 311Cys CETP-629C, ITGA2 873A, LTA 26Asn and LTA 252Gly remained independently associated with CKD, with respective hazard ratios (95% confidence interval):2
Introduction
Diabetes is a major cause of end-stage renal disease worldwide and contributes to a significant proportion of patients receiving renal replacement therapy. Suboptimal glycaemic control, long duration of disease and concurrent hypertension are reliable predictors of diabetic kidney disease [1, 2] . Recent studies have indicated that features of the metabolic syndrome, in particular, central obesity, dyslipidaemia and inflammation may also be involved in the progression of diabetic nephropathy [3] . Chinese patients with diabetes are more vulnerable to developing renal complications compared to their Western counterparts. Up to 60% of the Chinese diabetic population has albuminuria compared to 40% of the Caucasians [4] . Besides treatment factor, genetic variation may account for the ethnic differences in predisposition to diabetic nephropathy. Familial aggregation of diabetic kidney disease further highlights the importance of genetic factors in determining renal outcome [5] .
In this hypothesis-generating study involving 1386 Chinese patients with Type 2 diabetes followed up for 8 years, we examined the association of 107 single-nucleotide polymorphisms (SNPs) of 65 candidate genes with new-onset chronic kidney disease (CKD).
Materials and methods

Subjects
The study protocol was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong. Between 1 July 1994 and 30 June 1998, a consecutive cohort of 1386 Chinese Type 2 diabetic patients were enrolled into the Hong Kong Diabetes Registry with detailed documentation of risk factors, complications, drug use and clinical outcomes. Clinical samples were collected for routine laboratory and DNA assays. All subjects gave written informed consent and donated their DNA and clinical data for research and publication purposes.
Clinical and biochemical assessments
Detailed assessments of the subjects have been described [6] . In brief, clinical measurements and blood and urine samples were collected after 8 h of overnight fast. Retinopathy, sensory neuropathy and peripheral arterial disease were defined using standard methodologies [6] . Albumin to creatinine ratio (ACR) was measured using a random spot urine sample and confirmed by a subsequent timed urine collection (4 h or 24 h). Microalbuminuria was defined as ACR !3.5 mg/mmol for women and !2.5 mg/mmol for men, and macroalbuminuria was defined as ACR !25 mg/mmol. Estimated glomerular filtration rate (eGFR) was calculated using the Chinese- [7] .
Clinical end points
Hong Kong has a heavily subsidized health care system with 95% of health care provided by the Hospital Authority (HA), which governs all public hospitals and clinics. 
Genotyping
Genotyping was performed using line arrays from Roche Molecular Systems, Inc. A total of 107 SNPs in 65 candidate genes were selected based on putative association with lipid metabolism, inflammation, thrombosis, endothelial function, stress and natriuretic responses [8] . Genotypes were determined from the strips independently by two investigators. Fewer than 2% of the genotypes could not be determined conclusively.
Statistical analysis
Genotype call rate, Hardy-Weinberg equilibrium (HWE) and minor allele frequency for each SNP were assessed using PLINK (V.0.99, http:// pngu.mgh.harvard.edu/~purcell/plink/download.shtml) in the study population. After excluding 30 SNPs with either call rate <95% (n ¼ 6), HWE P value <0.05 (n ¼ 2), or minor allele frequency <0.01 (n ¼ 24) (Supplementary Table 2 ), 77 SNPs from 54 genes were included in the analysis (Supplementary Table 1 ).
All statistical analyses were performed using the SPSS Statistics 17.0 (SPSS, Chicago, IL) unless specified otherwise. Data are expressed as median (interquartile range, IQR) or percentages. Wilcoxon two sample test and chi-square tests were used as appropriate. The relationships between 77 SNPs under additive, dominant and recessive genetic models and new onset of CKD were tested by Cox proportional hazard regression model, with adjustment for baseline confounding factors including age, gender, duration of diabetes, smoking status, blood pressures, HbA 1c , Log10(triglyceride), high-density lipoprotein (HDL)-cholesterol, lowdensity lipoprotein (LDL)-cholesterol, Log10(1 1 ACR), Log10(eGFR), history of retinopathy, sensory neuropathy, peripheral arterial disease, stroke and coronary heart disease, as well as use of lipid-lowering agents, antihypertensive agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and insulin. Hazard ratios (HRs) with 95% confidence intervals (CIs) are presented. Multiple testings of SNPs under additive, dominant and recessive genetic models were corrected by permutation approach. The largest test statistic obtained from the three models was chosen (MAX statistic) [9] . Since the distribution of the MAX statistic under the null hypothesis is unknown, experimentwise significance was estimated from the empirical distribution of the MAX statistic after performing 10 000 permutations of genotypes for all 77 SNPs.
The effect of multiple SNPs on new onset of CKD was studied by weighted genetic risk score (wGRS) and number of risk alleles. Each SNP was weighted by b-coefficients obtained from the Cox proportional hazard regression model under the most significant genetic model. The wGRS was calculated by summing of the number of corresponding risk alleles multiplying by the weight of each SNP, where the weights
the number of corresponding risk alleles]. Multivariable Cox regression analyses were performed using the wGRS as a continuous and a categorical variable, respectively. The joint effect of SNPs for CKD risk is presented using Kaplan-Meier curves, which show the cumulative probability of newonset CKD according to number of risk alleles. The significance of the trend was tested by Cox regression using the categories of risk allele carried as an independent variable. A P-value <0.05 (two tailed) is considered significant.
The posterior study power was estimated for the six SNPs associated with incident CKD using genetic power calculator [10] .
Results
Among 1386 patients with Type 2 diabetes, 223 patients with history of CKD prior to enrolment were excluded from the analysis. In the remaining 1163 patients, 41.4% (n ¼ 481) were male, the median age was 57 (IQR: 47-65) years and median disease duration was 8.0 (IQR: 2-12) years. After a median follow-up period of 8.3 (IQR: 5.8-9.3) years, 235 patients (20.2% or 27.5 per 1000 person-year) developed CKD. Patients who progressed to CKD were significantly older, had a longer duration of diabetes, higher BP, worse glycaemic control and lipid profile, higher urine ACR, lower eGFR and were more likely to have micro-and marcovascular complications at baseline compared to those who did not develop CKD (Table 1 ).
All genotypes of the 77 SNPs analysed were in HWE (P > 0.01). In Cox-regression analysis, after controlling for baseline confounding variables, 15 SNPs of 13 genes were significantly associated with incident CKD (Table 2) . These SNPs include IL10 (interleukin 10) -592C>A, PON1 (paraoxonase 1) Met55Leu, PON2 (paraoxonase 2) Ser311Cys, CETP (cholesteryl ester transfer protein) -629C>A, CETP Ile405Val, PPARG (peroxisome proliferator activated receptor c) Pro12Ala and VCAM1 (vascular cell adhesion molecule 1) 707T>C under an additive model; UGB (uteroglobin) 587G>A, IL1B (interleukin 1b) -511C>T, APOB (apolipoprotein B) Thr71Ile, NOS3 (endothelial nitric oxide synthase) -786T>C, LTA (lymphotoxin a) Thr26Asn and LTA Ala252Gly under a dominant model as well as ITGA2 (intergrin a2b1) 873G>A and SELE (endothelial adhesion molecule 1) Leu554Phe under a recessive model. The minor allele frequencies of APOB Thr71Ile and VCAM1 707T>C were significantly higher in patients with new-onset CKD than the patients without CKD (Table 1) . After correction for multiple comparisons using permutation, six SNPs including PON1 55Met, PON2 311Cys, CETP-629C; LTA 26Asn, LTA 252Gly and ITGA2 873A remained significantly associated with progression to CKD, with respective HRs (95% CI) of 2.60 (1.41-4.80, P ¼ 0.002), 1.48 (1.15-1.92, P ¼ 0.003), 1.38 (1.13-1.69, P ¼ 0.001), 1.55 (1.12-2.15, P ¼ 0.008), 1.48 (1.07-2.05, P ¼ 0.019) and 2.23 (1.34-3.73 P ¼ 0.002) ( Table 2 ). Compared to PON1 55Leu carriers, the PON1 55Met carriers had higher mean level of plasma cholesterol (LDL-C) (3.71 AE 1.16 mmol/L versus 3.43
The joint effect of the risk alleles of six polymorphisms on new onset of CKD was further examined using wGRS and number of risk alleles. The six SNPs were weighted by the relevant b-coefficient: 0.956 (PON1 Met55Leu), 0.392 (PON2 Ser311Cys), 0.322 (CETP -629C>A), 0.802 (ITGA2 873G>A), 0.438 (LTA Thr26Asn) and 0.392 (LTA Ala252Gly). After adjustment for baseline-confounding variables, each additional unit of the wGRS (mean ¼ 2.43, range ¼ 0-7.12) was associated with a 37.2% increase in CKD risk (P ¼ 5.2 3 10
À7
). There was a significant increased risk of CKD with increasing number of risk alleles (P trend ¼ 8.9 3 10 À7 ) ( Figure 1) . A similar trend was observed when the analysis was performed by using wGRS (P trend ¼ 4.0 3 10
À5
). Compared to patients carrying zero to two risk alleles or in the lowest quartile of wGRS, the adjusted risk for CKD was 3.2 (95% CI 1.97-5.07, P ¼ 2.0 3 10 À6 ) and 2.5 (95% CI 1.56-3.85, P ¼ 1.0 3 10
À4
) for patients carrying five or more risk alleles, or in the highest quartile of wGRS, respectively (Table 3) .
With the lowest allele frequency of 2.6% (PON1 55Met) and the highest frequency of 54.0% (CETP-629C) among the six SNPs, the estimation of posterior study power showed that our sample size had 68.5-99.0% power to detect an HR of 1.4-2.6 for CKD at a level of 0.05. 
Discussion
In this cohort of Chinese patients with Type 2 diabetes who had normal renal function at baseline, one-fifth developed CKD after 8 years of follow-up. A recently published population-based study conducted in the USA reported an incidence rate of CKD, as defined based on eGFR <60 mL/ min/1.73m 2 or hospitalization with renal disease, of 17.0 cases per 1000 person-year among subjects with diabetes [2] . This was appreciably lower than the rate of 27.5 cases per 1000 person-year obtained in the present cohort. Genetic factor is an important contributor to the observed ethnic disparity of renal risk. The study of genes that potentially influence the evolution of diabetic complications is now an area of emerging interest in diabetes research.
In our study, we have chosen genes related to processes important in the pathogenesis of diabetic kidney disease, including inflammation, lipid metabolism, thrombosis and vascular tone regulation. Of note, these pathways are also fundamental in the development of atherosclerosis. Indeed, diabetic nephropathy is analogous in many aspects to atherosclerosis with considerable overlap of risk factors. Of the 77 SNPs analysed, 15 SNPs of 13 genes were found to be significantly correlated with incident CKD. After controlling for multiple statistical comparison using permutation procedure, only six SNPs (PON1 Met55Leu, PON2 Ser311Cys, CETP-629C>A, ITGA2 873G>A, LTA Thr26Asn and LTA Ala252Gly) remained significantly associated with CKD, independently conferring 1.4-2.6-fold risk. Of relevance, both CETP-629C>A and LTA Ala252Gly were reported to associate with renal function in our recent analysis of genotype-phenotype interaction by non-linear structural equation modelling [11] .
Paraoxonase 1, paraoxonase 2 and cholesterol ester transfer protein are involved in lipid metabolism. Increasing evidences are gathering to support the hazardous effect of lipid accumulation in renal tissues leading to irreversible renal injury [12, 13] . Excess lipid deposition in renal parenchyma results in up-regulation of inflammatory cytokines, which in turn stimulate macrophage infiltration and foam cell formation. Moreover, direct interaction of lipoproteins with receptors expressed on mesangial cells triggers mesangial cell proliferation and matrix deposition [12] . Cholesteryl ester transfer protein is primarily responsible for reverse cholesterol transport, a mechanism by which cholesterol from peripheral tissues is delivered to the liver for elimination [14] . Through its action, cholesteryl ester is exchanged for triglyceride from HDL to apo-B-containing lipoproteins. The CETP gene is located in long arm of chromosome 16 and the CETP -629C>A has been identified as a functional polymorphism [15] . Carriers of -629C allele have raised CETP activity and lower HDLcholesterol levels [16] . In our analysis, -629CC homozygotes were at 1.4-fold increased risk of developing CKD compared to -629AA homozygotes. We also found that patients who developed CKD had lower HDL-cholesterol and higher triglyceride levels at baseline. There were, however, no discernable differences in lipid levels between the two genotypes (data not shown). Higher CETP activity has been reported in Type 1 diabetic patients with nephropathy compared to without nephropathy [17] . In a separate study of 494 patients with Type 1 diabetes, no association between the CETP Taq1B genotype, which is in strong linkage disequilibrium with -629C>A, and nephropathy was found [18] . Paraoxonases are encoded by gene cluster located on chromosome 7q21-q22 [19] . There is considerable overlap of the amino acid sequences among the three PON genes (PON1, PON2 and PON3), denoting similarities in biological function. Paraoxonase-1, as a component of circulating HDL, is responsible for the anti-oxidative action of HDL by inhibiting LDL oxidation [20] . In keeping with previous studies that reported lower PON1 activity, higher triglyceride and LDL-cholesterol levels in diabetic carriers of PON1 55Met [21] , we also showed that PON1 55Met carriers had higher LDL-cholesterol levels compared to PON1 55Leu carriers (3.71 AE 1.16 mmol/L versus 3.43 AE 0.99 mmol/L, P ¼ 0.035). Reduced PON1 activity was shown to be an independent risk factor for diabetic micro-or macroangiopathy [21] . Published studies in Type 1 diabetic patients nevertheless failed to confirm an association between PON1 genotypes and risk of renal complications [22, 23] . Unlike PON1 which is present in the circulation, PON2 is confined to the intracellular compartment and is ubiquitously expressed in a wide variety of human tissues. Cells overexpressing PON2 exhibited less intracellular oxidative stress when subjected to treatment with hydrogen peroxide or oxidized phospholipids [24] . Oxidative stress is one of the key intermediary processes in development of diabetic nephropathy [25] and is associated with increased macrophage-mediated oxidation of LDL and uptake of oxidized LDL into macrophages. We found that PON2 311Cys confers an elevated risk of CKD. This finding concurs with two other studies that demonstrated increased susceptibility to microangiopathy in carriers of PON2 311Cys [26, 27] .
Lymphotoxin-alpha is a member of the tumour necrosis factor (TNF) superfamily of pro-inflammatory cytokines. The LTA gene is located close to the TNF-a gene within the human leucocyte antigen class III gene cluster on chromosome 6p [28] . Polymorphisms of LTA Thr26Asn in Intron 1 and Ala252Gly in Exon 3 are in tight linkage disequilibrium [29] . Functional studies showed that LTA 252Gly-containing haplotype enhanced the transcriptional level of LTA [30] and was associated with higher levels of C-reactive protein [31] and TNF-alpha [32] . Moreover, LTA 252Gly was associated with increased risk of cardiovascular diseases and with components of the metabolic syndrome including insulin resistance, low HDL and high triglyceride levels [30, 33, 34] . The role of chronic inflammation in the pathogenesis of diabetic nephropathy has been extensively investigated. Markers of inflammation such as white blood cell count [35] and CRP levels [36] are positively related to nephropathy. In line with these findings, a recent study demonstrated 2.5-fold increased risk of diabetic nephropathy among Type 1 but not Type 2 diabetic patients of the Scandinavian ancestry carrying LTA 26Asn allele [37] . Our study showed that the LTA 252Gly and LTA 26Asn under dominant model conferred 50% excess risk for developing CKD, thus provides further evidence for the role of LTA polymorphism in diabetic microvascular complication. Integrin a2b1, expressed on platelet surface, facilitates platelet adhesion to subendothelial collagen in the presence of endothelial damage. The ITGA2 gene is located on chromosome 5q23-q31 and carries two silent polymorphisms 873G>A and 807C>T in the coding domain [38] and a BglII polymorphism in the intronic region [39] . These three polymorphisms are in complete linkage disequilibrium, with the 873A allele being linked to the 807T allele and the BglII (1) allele. Given that the ITGA2 807 T (873 A or BglII 1) allele correlates with higher density of integrin a2b1, allelic variation may influence platelet adhesion potential and thus, thrombotic tendency [39] . Among Japanese Type 2 diabetic patients with long disease duration, the presence of BglII(1) allele was associated with increased risk of retinopathy and nephropathy [40] . However, a subsequent study conducted in a Chinese population failed to confirm an association of the ITGA2 polymorphism with diabetic renal complications [41] . In our prospective cohort, carriers of 873 AA genotype had 2.2-fold increased risk of CKD compared to patients carrying AG or GG genotype. The precise mechanisms linking platelet function and diabetic renal disease are not fully understood. Thrombosis in the renal microvasculature may affect renal haemodynamics and contribute to organ damage.
Our study has several limitations. Firstly, as this study involves simultaneous statistical comparisons of a large number of SNPs in three genetic models (recessive, additive and dominant), it is possible that SNPs tested significant for association with CKD occurs by chance alone. Permutation testing is an accepted procedure to correct for multiple comparisons and this was applied to all tested SNPs. Secondly, despite biological plausibility of the risk variants identified, it is plausible that one or more of the SNPs are in linkage disequilibrium with other yet-unknown functional mutation(s) in the vicinity that contribute to the development of CKD. Thirdly, this study does not provide direct biological evidence to explain the risk conferred by the individual genetic variants. The study of the mechanisms leading to development of diabetic nephropathy in relation to altered expression of the implicated genes would require independent functional studies. Fourthly, while diabetes may be the main cause of new onset CKD in this cohort, it remains possible that non-diabetic aetiologies may contribute to renal deterioration in a subset of patients. Lastly, as this study was conducted in Chinese patients with diabetes, the results cannot be extrapolated to non-Chinese population and individuals without diabetes in the absence of replication. The key strength of our study lies in the detailed characterization of patients' phenotypes and in the long duration of patient follow-up. We considered our results robust as the associations remained significant after correction for baseline variables and multiple testing. The stepwise increase in risk with the accumulation of risk variants adds strength to our findings.
Summarizing, in this relatively large prospective cohort of Chinese diabetic patients, we observed significant association between genetic polymorphisms in PON1, PON2, CETP, ITGA2 and LTA and incident CKD. Our results highlighted the role of multiple pathways related to lipid metabolism, oxidative stress, inflammation and haemostasis in the development of CKD in patients with Type 2 diabetes. As this is an exploratory study, replication in independent population is necessary to confirm the validity of our results.
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